HIV/AIDS Topics May 18 is HIV Vaccine Awareness Day
- Details
- Category: HIV Prevention
- Published on Sunday, 17 May 2015 00:00
- Written by HIVandHepatitis.com
May 18 is HIV Vaccine Awareness Day, an annual opportunity to call attention to progress in vaccine science and the need for further research on both preventive vaccines that stop new HIV infections and therapeutic vaccines that help the immune system fight existing infection.
Study Suggests Truvada PrEP Should Start 1 Week Before and Continue 4 Weeks After Sex
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 06 May 2015 00:00
- Written by Liz Highleyman
An intensive pharmacokinetic study of tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) showed that blood and rectal drugs levels corresponding to high PrEP activity for men who have sex with men (MSM) are reached after about 1 week of daily dosing and appear to remain adequate for several days after the last pill, according to a report in the March 1 edition of Clinical Infectious Diseases. It is not known, however, whether this dosing schedule would work as well for women or other groups.
CROI 2015: Daily PrEP Leads to Better Adherence and Protective Drug Levels in Women
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 17 April 2015 00:00
- Written by Liz Highleyman
HIV-negative African women assigned to take once-daily Truvada for HIV pre-exposure prophylaxis (PrEP) achieved better adherence than those assigned to take PrEP twice-weekly or before and after sex, according to findings from the HPTN 067 trial presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
BHIVA 2015: HIV+ Men on Antiretroviral Treatment Have Undetectable Rectal Viral Load
- Details
- Category: HIV Sexual Transmission
- Published on Monday, 27 April 2015 00:00
- Written by Roger Pebody
A small study assessing the infectiousness of HIV-positive gay men taking antiretroviral therapy has found that all study participants had an undetectable viral load in the rectum, according to a presentation at the British HIV Association (BHIVA) conference last week in Brighton. Men who had rectal gonhorrea or chlamydia did not have detectable virus either, suggesting that concerns about sexually transmitted infections raising the risk of HIV transmission may be unfounded when people are taking effective HIV treatment.
Women in PrEP Trial Feared Having to Leave Study if They Reported Low Adherence
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 17 April 2015 00:00
- Written by Gus Cairns
Post-study interviews and computer questionnaires conducted with former participants in the Fem-PrEP trial of pre-exposure prophylaxis (PrEP) that reported zero effectiveness show that the women concealed their low adherence because -- despite reassurances from researchers -- they feared they would be asked to leave the study, according to a report in the April 2015 Journal of Acquired Immune Deficiency Syndromes.
More Articles...
- HIV Risk Behavior Remains Common Among People Who Inject Drugs in U.S.
- Some Providers Remain Reluctant to Prescribe HIV Pre-Exposure Prophylaxis
- Study Suggests HIV May Be Less Infectious than Assumed During Early Infection
- CROI 2015: Circumcision is Reducing HIV Incidence in Uganda, Rakai Community Study Shows
Web Design and Development by